Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Selin Somersan

Showing results (11-20 of 28) with videos related to

Pageof 3
Sort By:
Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.
European Journal of Medicinal Chemistry|February 22, 2014
Benzimidazole-based compounds kill Mycobacterium tuberculosisYaling Gong, Selin Somersan Karakaya, Xiaoyong Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2017
Rifamycin action on RNA polymerase in antibiotic-tolerant <i>Mycobacterium tuberculosis</i> results in differentially detectable populationsKohta Saito, Thulasi Warrier, Selin Somersan-Karakaya, et al.
Mbio|October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesAndrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Journal of Medicinal Chemistry|May 5, 2016
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosisBen Gold, Robert Smith, Quyen Nguyen, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
ACS Infectious Diseases|September 14, 2016
Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosisThulasi Warrier, Maria Martinez-Hoyos, Manuel Marin-Amieva, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobialsBen Gold, Maneesh Pingle, Steven J Brickner, et al.
ACS Infectious Diseases|February 22, 2018
Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosisAna Negri, Prisca Javidnia, Ran Mu, et al.
Ebiomedicine|September 13, 2024
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19Bei Wang, Jacquelynn Golubov, Erin M Oswald, et al.
Pageof 3

Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Journal of Patient-Reported Outcomes|August 8, 2024
The symptoms evolution of long COVID‑19 (SE-LC19): a new patient-reported content valid instrumentDiana Rofail, Selin Somersan-Karakaya, Eleftherios Mylonakis, et al.
European Journal of Medicinal Chemistry|February 22, 2014
Benzimidazole-based compounds kill Mycobacterium tuberculosisYaling Gong, Selin Somersan Karakaya, Xiaoyong Guo, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 1, 2017
Rifamycin action on RNA polymerase in antibiotic-tolerant <i>Mycobacterium tuberculosis</i> results in differentially detectable populationsKohta Saito, Thulasi Warrier, Selin Somersan-Karakaya, et al.
Mbio|October 18, 2022
Casirivimab and Imdevimab Treatment Reduces Viral Load and Improves Clinical Outcomes in Seropositive Hospitalized COVID-19 Patients with Nonneutralizing or Borderline Neutralizing AntibodiesAndrea T Hooper, Selin Somersan-Karakaya, Shane E McCarthy, et al.
Journal of Medicinal Chemistry|May 5, 2016
Novel Cephalosporins Selectively Active on Nonreplicating Mycobacterium tuberculosisBen Gold, Robert Smith, Quyen Nguyen, et al.
Open Forum Infectious Diseases|May 25, 2023
Effectiveness of Casirivimab and Imdevimab Antibody Combination in Immunocompromised Hospitalized Patients With Coronavirus Disease 2019: A Post Hoc Analysis in a Phase 1/2/3 Double-Blind TrialSelin Somersan-Karakaya, Eleftherios Mylonakis, Jenni Mou, et al.
ACS Infectious Diseases|September 14, 2016
Identification of Novel Anti-mycobacterial Compounds by Screening a Pharmaceutical Small-Molecule Library against Nonreplicating Mycobacterium tuberculosisThulasi Warrier, Maria Martinez-Hoyos, Manuel Marin-Amieva, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 27, 2012
Nonsteroidal anti-inflammatory drug sensitizes Mycobacterium tuberculosis to endogenous and exogenous antimicrobialsBen Gold, Maneesh Pingle, Steven J Brickner, et al.
ACS Infectious Diseases|February 22, 2018
Identification of a Mycothiol-Dependent Nitroreductase from Mycobacterium tuberculosisAna Negri, Prisca Javidnia, Ran Mu, et al.
Ebiomedicine|September 13, 2024
Potential immunomodulatory effects of CAS+IMD monoclonal antibody cocktail in hospitalized patients with COVID-19Bei Wang, Jacquelynn Golubov, Erin M Oswald, et al.
Pageof 3